Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
anticonvulsant |
| gptkbp:activeIngredient |
gptkb:tiagabine
|
| gptkbp:approvalYear |
1997 (US)
|
| gptkbp:ATCCode |
N03AG06
|
| gptkbp:brand |
gptkb:Gabitril
|
| gptkbp:CASNumber |
145821-59-6
|
| gptkbp:chemicalFormula |
C20H25NO2S2·HCl
|
| gptkbp:contraindication |
hypersensitivity to tiagabine
|
| gptkbp:developer |
gptkb:Novo_Nordisk
gptkb:Cephalon |
| gptkbp:eliminationHalfLife |
7-9 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
tiagabine hydrochloride
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
GABA reuptake inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
412.01 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
tremor nervousness somnolence asthenia |
| gptkbp:usedFor |
epilepsy
|
| gptkbp:bfsParent |
gptkb:tiagabine
|
| gptkbp:bfsLayer |
7
|